Bulletin
Investor Alert

Gilead Sciences Inc.

NAS: GILD

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 28, 2022, 7:59 p.m.

/zigman2/quotes/210293917/composite

$

69.00

Change

+0.14 +0.20%

Volume

Volume 298,091

Quotes are delayed by 20 min

/zigman2/quotes/210293917/composite

Today's close

$ 67.27

$ 68.86

Change

+1.59 +2.36%

Day low

Day high

$67.02

$68.87

Open

52 week low

52 week high

$61.39

$74.12

Open

Company Description

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology,...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Valuation

P/E Current

690.73

P/E Ratio (with extraordinary items)

11.48

P/E Ratio (without extraordinary items)

598.15

Price to Sales Ratio

2.99

Price to Book Ratio

4.01

Price to Cash Flow Ratio

9.01

Enterprise Value to EBITDA

9.08

Enterprise Value to Sales

3.93

Total Debt to Enterprise Value

0.33

Efficiency

Revenue/Employee

1,811,912.00

Income Per Employee

9,044.00

Receivables Turnover

5.81

Total Asset Turnover

0.38

Liquidity

Current Ratio

1.40

Quick Ratio

1.26

Cash Ratio

0.72

Profitability

Gross Margin

81.70

Operating Margin

42.38

Pretax Margin

6.77

Net Margin

0.50

Return on Assets

0.19

Return on Equity

0.60

Return on Total Capital

21.25

Return on Invested Capital

0.27

Capital Structure

Total Debt to Total Equity

176.45

Total Debt to Total Capital

63.83

Total Debt to Total Assets

46.95

Long-Term Debt to Equity

160.71

Long-Term Debt to Total Capital

58.14

Officers and Executives

Name Age Officer Since Title
Mr. Daniel P. O'Day 55 2019 Chairman & Chief Executive Officer
Mr. Andrew D. Dickinson 49 2016 Chief Financial Officer
Dr. Merdad V. Parsey - 2019 Chief Medical Officer
Dr. Flavius Martin - 2021 Executive Vice President-Research
Ms. Johanna Mercier 50 2019 Chief Commercial Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/08/2021 Jeffrey A. Bluestone
Director
1,041   Derivative/Non-derivative trans. at $0 per share. 0
11/10/2021 Andrew D. Dickinson
Chief Financial Officer
870   Derivative/Non-derivative trans. at $67.32 per share. 58,568
11/10/2021 Merdad V. Parsey
Chief Medical Officer
2,320   Derivative/Non-derivative trans. at $67.32 per share. 156,182
11/10/2021 Andrew D. Dickinson
Chief Financial Officer
1,913   Derivative/Non-derivative trans. at $0 per share. 0
11/10/2021 Merdad V. Parsey
Chief Medical Officer
5,100   Derivative/Non-derivative trans. at $0 per share. 0
10/22/2021 Anthony Welters
Director
1,368   Derivative/Non-derivative trans. at $0 per share. 0
08/17/2021 Diane E. Wilfong
SVP, Controller & CAO
13,610   Disposition at $72.5 per share. 986,725
08/17/2021 Diane E. Wilfong
SVP, Controller & CAO
3,829   Derivative/Non-derivative trans. at $66.36 per share. 254,092
08/17/2021 Diane E. Wilfong
SVP, Controller & CAO
9,781   Derivative/Non-derivative trans. at $68.75 per share. 672,443
08/15/2021 Andrew D. Dickinson
Chief Financial Officer
1   Award at $55.08 per share. 55
08/15/2021 Brett A. Pletcher
EVP,Corp Affairs & Gen Counsel
32   Award at $55.08 per share. 1,762
08/15/2021 Merdad V. Parsey
Chief Medical Officer
1   Award at $55.08 per share. 55
08/10/2021 Diane E. Wilfong
SVP, Controller & CAO
907   Derivative/Non-derivative trans. at $69.24 per share. 62,800
08/10/2021 Diane E. Wilfong
SVP, Controller & CAO
2,480   Derivative/Non-derivative trans. at $0 per share. 0
07/24/2021 Johanna Mercier
Chief Commercial Officer
3,425   Derivative/Non-derivative trans. at $69.02 per share. 236,393
07/24/2021 Johanna Mercier
Chief Commercial Officer
7,505   Derivative/Non-derivative trans. at $0 per share. 0
06/15/2021 Javier J. Rodriguez
Director
1,838   Derivative/Non-derivative trans. at $0 per share. 0
06/10/2021 Andrew D. Dickinson
Chief Financial Officer
1,605   Derivative/Non-derivative trans. at $69.29 per share. 111,210
06/10/2021 Andrew D. Dickinson
Chief Financial Officer
3,646   Derivative/Non-derivative trans. at $0 per share. 0
05/06/2021 Per Wold-Olsen
Director
1,936   Derivative/Non-derivative trans. at $0 per share. 0
05/06/2021 Richard J. Whitley
Director
1,936   Derivative/Non-derivative trans. at $0 per share. 0
05/06/2021 Jacqueline K. Barton
Director
1,936   Derivative/Non-derivative trans. at $0 per share. 0
05/06/2021 Harish M. Manwani
Director
1,936   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/gild

MarketWatch News on GILD

  1. Gilead Sciences Inc. stock rises Friday, still underperforms market

    4:56 p.m. Today

    - MarketWatch Automation

  2. AstraZeneca PLC ADR falls Friday, underperforms market

    4:38 p.m. Today

    - MarketWatch Automation

  3. AstraZeneca PLC ADR outperforms competitors on strong trading day

    4:39 p.m. Jan. 27, 2022

    - MarketWatch Automation

  4. Gilead Sciences Inc. stock falls Wednesday, underperforms market

    4:56 p.m. Jan. 26, 2022

    - MarketWatch Automation

  5. AstraZeneca PLC ADR falls Wednesday, underperforms market

    4:38 p.m. Jan. 26, 2022

    - MarketWatch Automation

  6. Gilead Sciences Inc. stock outperforms market on strong trading day

    4:56 p.m. Jan. 25, 2022

    - MarketWatch Automation

  7. AstraZeneca PLC ADR rises Tuesday, outperforms market

    4:38 p.m. Jan. 25, 2022

    - MarketWatch Automation

  8. Gilead Sciences Inc. stock rises Monday, still underperforms market

    4:56 p.m. Jan. 24, 2022

    - MarketWatch Automation

  9. Gilead Sciences Inc. stock outperforms competitors on strong trading day

    4:56 p.m. Jan. 21, 2022

    - MarketWatch Automation

  10. AstraZeneca PLC ADR underperforms Friday when compared to competitors

    4:38 p.m. Jan. 21, 2022

    - MarketWatch Automation

  11. AstraZeneca PLC ADR rises Thursday, outperforms market

    4:38 p.m. Jan. 20, 2022

    - MarketWatch Automation

  12. Gilead Sciences Inc. stock falls Wednesday, underperforms market

    4:56 p.m. Jan. 19, 2022

    - MarketWatch Automation

  13. AstraZeneca PLC ADR falls Wednesday, still outperforms market

    4:39 p.m. Jan. 19, 2022

    - MarketWatch Automation

  14. Gilead Sciences Inc. stock falls Tuesday, underperforms market

    4:56 p.m. Jan. 18, 2022

    - MarketWatch Automation

  15. Loading more headlines...
/news/nonmarketwatch/company/us/gild

Other News on GILD

  1. Should You Buy Gilead Sciences (GILD) Ahead of Earnings?

    11:23 a.m. Today

    - Zacks.com

  2. Pfizer (PFE) Gets CHMP Recommendation for COVID Pill Paxlovid

    11:18 a.m. Today

    - Zacks.com

  3. Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards?

    10:20 a.m. Today

    - Zacks.com

  4. 5 Corporate Giants Likely to Gain From Q4 Earnings Next Week

    6:42 a.m. Today

    - Zacks.com

  5. CD47 And Immuno-Oncology Therapies

    3:20 a.m. Today

    - Seeking Alpha

  6. Gilead's (GILD) Magrolimab Studies Put on Hold by the FDA

    8:29 a.m. Jan. 27, 2022

    - Zacks.com

  7. LABU - A Compelling Biotech Trade

    4:24 p.m. Jan. 26, 2022

    - Seeking Alpha

  8. Why Sierra Oncology Stock Is On Fire Today

    9:12 a.m. Jan. 25, 2022

    - Motley Fool

  9. Loading more headlines...

At a Glance

Gilead Sciences, Inc.

333 Lakeside Drive

Foster City, California 94404

Phone

1 6505743000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$24.64B

Net Income

$123.00M

2020 Sales Growth

10.4%

Employees

13,600

/news/pressrelease/company/us/gild

Press Releases on GILD

  1. Nasdaq 100 Movers: ADP, DDOG

    10:43 a.m. Jan. 26, 2022

    - MarketNewsVideo.com

  2. How To Trade Gilead Sciences GILD

    5:55 p.m. Jan. 21, 2022

    - Stock Traders Daily

  3. Nasdaq 100 Movers: GILD, PDD

    10:26 a.m. Jan. 19, 2022

    - MarketNewsVideo.com

  4. How the price action of Gilead Sciences (GILD) is used to our Advantage

    11:35 p.m. Jan. 11, 2022

    - Stock Traders Daily

  5. Gilead Sciences GILD Technical Analysis

    5:21 a.m. Jan. 2, 2022

    - Stock Traders Daily

  6. Gilead Sciences GILD Proactive Strategies

    9:57 a.m. Dec. 23, 2021

    - Stock Traders Daily

  7. Loading more headlines...
Link to MarketWatch's Slice.